Oscillating  ||| S:0 E:12 ||| JJ
field  ||| S:12 E:18 ||| NN
stimulation  ||| S:18 E:30 ||| NN
in  ||| S:30 E:33 ||| IN
the  ||| S:33 E:37 ||| DT
treatment  ||| S:37 E:47 ||| NN
of  ||| S:47 E:50 ||| IN
spinal  ||| S:50 E:57 ||| JJ
cord  ||| S:57 E:62 ||| NN
injury  ||| S:62 E:69 ||| NN
The  ||| S:69 E:73 ||| DT
application  ||| S:73 E:85 ||| NN
of  ||| S:85 E:88 ||| IN
electrical  ||| S:88 E:99 ||| JJ
current  ||| S:99 E:107 ||| JJ
to  ||| S:107 E:110 ||| TO
injured  ||| S:110 E:118 ||| JJ
tissue  ||| S:118 E:125 ||| NN
is  ||| S:125 E:128 ||| VBZ
known  ||| S:128 E:134 ||| VBN
to  ||| S:134 E:137 ||| TO
promote  ||| S:137 E:145 ||| VB
healing ||| S:145 E:152 ||| NN
.  ||| S:152 E:154 ||| .
The  ||| S:154 E:158 ||| DT
use  ||| S:158 E:162 ||| NN
of  ||| S:162 E:165 ||| IN
this  ||| S:165 E:170 ||| DT
modality  ||| S:170 E:179 ||| NN
in  ||| S:179 E:182 ||| IN
healing  ||| S:182 E:190 ||| VBG
the  ||| S:190 E:194 ||| DT
injured  ||| S:194 E:202 ||| JJ
spinal  ||| S:202 E:209 ||| JJ
cord  ||| S:209 E:214 ||| NN
to  ||| S:214 E:217 ||| TO
promote  ||| S:217 E:225 ||| VB
neurologic  ||| S:225 E:236 ||| JJ
recovery  ||| S:236 E:245 ||| NN
has  ||| S:245 E:249 ||| VBZ
been  ||| S:249 E:254 ||| VBN
introduced  ||| S:254 E:265 ||| VBN
as  ||| S:265 E:268 ||| IN
a  ||| S:268 E:270 ||| DT
potential  ||| S:270 E:280 ||| JJ
treatment  ||| S:280 E:290 ||| NN
for  ||| S:290 E:294 ||| IN
patients  ||| S:294 E:303 ||| NNS
who  ||| S:303 E:307 ||| WP
previously  ||| S:307 E:318 ||| RB
had  ||| S:318 E:322 ||| VBD
minimal  ||| S:322 E:330 ||| JJ
hope  ||| S:330 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
recovery ||| S:338 E:346 ||| NN
.  ||| S:346 E:348 ||| .
In  ||| S:348 E:351 ||| IN
in  ||| S:351 E:354 ||| IN
vitro  ||| S:354 E:360 ||| NN
and  ||| S:360 E:364 ||| CC
in  ||| S:364 E:367 ||| IN
vivo  ||| S:367 E:372 ||| JJ
experiments ||| S:372 E:383 ||| NNS
,  ||| S:383 E:385 ||| ,
neural  ||| S:385 E:392 ||| JJ
regeneration  ||| S:392 E:405 ||| NN
has  ||| S:405 E:409 ||| VBZ
been  ||| S:409 E:414 ||| VBN
seen  ||| S:414 E:419 ||| VBN
to  ||| S:419 E:422 ||| TO
occur ||| S:422 E:427 ||| VB
,  ||| S:427 E:429 ||| ,
especially  ||| S:429 E:440 ||| RB
when  ||| S:440 E:445 ||| WRB
an  ||| S:445 E:448 ||| DT
oscillating  ||| S:448 E:460 ||| JJ
field  ||| S:460 E:466 ||| NN
is  ||| S:466 E:469 ||| VBZ
used ||| S:469 E:473 ||| VBN
.  ||| S:473 E:475 ||| .
With  ||| S:475 E:480 ||| IN
this  ||| S:480 E:485 ||| DT
modality ||| S:485 E:493 ||| NN
,  ||| S:493 E:495 ||| ,
an  ||| S:495 E:498 ||| DT
electrical  ||| S:498 E:509 ||| JJ
current  ||| S:509 E:517 ||| NN
is  ||| S:517 E:520 ||| VBZ
applied  ||| S:520 E:528 ||| VBN
in  ||| S:528 E:531 ||| IN
which  ||| S:531 E:537 ||| WDT
the  ||| S:537 E:541 ||| DT
polarity  ||| S:541 E:550 ||| JJ
changes  ||| S:550 E:558 ||| NNS
direction  ||| S:558 E:568 ||| NN
on  ||| S:568 E:571 ||| IN
a  ||| S:571 E:573 ||| DT
periodic  ||| S:573 E:582 ||| JJ
basis ||| S:582 E:587 ||| NN
,  ||| S:587 E:589 ||| ,
preventing  ||| S:589 E:600 ||| VBG
the  ||| S:600 E:604 ||| DT
die-back  ||| S:604 E:613 ||| JJ
phenomenon  ||| S:613 E:624 ||| NN
of  ||| S:624 E:627 ||| IN
severed  ||| S:627 E:635 ||| JJ
neural  ||| S:635 E:642 ||| JJ
pathways ||| S:642 E:650 ||| NN
.  ||| S:650 E:652 ||| .
This  ||| S:652 E:657 ||| DT
mechanism  ||| S:657 E:667 ||| NN
of  ||| S:667 E:670 ||| IN
recovery  ||| S:670 E:679 ||| NN
has  ||| S:679 E:683 ||| VBZ
been  ||| S:683 E:688 ||| VBN
demonstrated  ||| S:688 E:701 ||| VBN
in  ||| S:701 E:704 ||| IN
several  ||| S:704 E:712 ||| JJ
species  ||| S:712 E:720 ||| NNS
in  ||| S:720 E:723 ||| IN
which  ||| S:723 E:729 ||| WDT
sacrifice  ||| S:729 E:739 ||| NN
has  ||| S:739 E:743 ||| VBZ
been  ||| S:743 E:748 ||| VBN
undertaken  ||| S:748 E:759 ||| VBN
and  ||| S:759 E:763 ||| CC
spinal  ||| S:763 E:770 ||| JJ
cords  ||| S:770 E:776 ||| NN
examined ||| S:776 E:784 ||| VBD
.  ||| S:784 E:786 ||| .
In  ||| S:786 E:789 ||| IN
a  ||| S:789 E:791 ||| DT
study  ||| S:791 E:797 ||| NN
of  ||| S:797 E:800 ||| IN
humans ||| S:800 E:806 ||| NNS
,  ||| S:806 E:808 ||| ,
a  ||| S:808 E:810 ||| DT
small  ||| S:810 E:816 ||| JJ
number  ||| S:816 E:823 ||| NN
of  ||| S:823 E:826 ||| IN
patients  ||| S:826 E:835 ||| NNS
participated  ||| S:835 E:848 ||| VBD
in  ||| S:848 E:851 ||| IN
a  ||| S:851 E:853 ||| DT
single  ||| S:853 E:860 ||| JJ
phase  ||| S:860 E:866 ||| NN
Ia  ||| S:866 E:869 ||| NNP
trial  ||| S:869 E:875 ||| NN
in  ||| S:875 E:878 ||| IN
which  ||| S:878 E:884 ||| WDT
the  ||| S:884 E:888 ||| DT
safety  ||| S:888 E:895 ||| NN
of  ||| S:895 E:898 ||| IN
an  ||| S:898 E:901 ||| DT
implantable  ||| S:901 E:913 ||| JJ
device  ||| S:913 E:920 ||| NN
was  ||| S:920 E:924 ||| VBD
demonstrated ||| S:924 E:936 ||| VBN
,  ||| S:936 E:938 ||| ,
with  ||| S:938 E:943 ||| IN
indications  ||| S:943 E:955 ||| NNS
of  ||| S:955 E:958 ||| IN
probable  ||| S:958 E:967 ||| JJ
benefit ||| S:967 E:974 ||| NN
,  ||| S:974 E:976 ||| ,
consistent  ||| S:976 E:987 ||| JJ
with  ||| S:987 E:992 ||| IN
laboratory  ||| S:992 E:1003 ||| NN
and  ||| S:1003 E:1007 ||| CC
animal  ||| S:1007 E:1014 ||| JJ
studies ||| S:1014 E:1021 ||| NNS
.  ||| S:1021 E:1023 ||| .
In  ||| S:1023 E:1026 ||| IN
addition ||| S:1026 E:1034 ||| NN
,  ||| S:1034 E:1036 ||| ,
a  ||| S:1036 E:1038 ||| DT
number  ||| S:1038 E:1045 ||| NN
of  ||| S:1045 E:1048 ||| IN
additional  ||| S:1048 E:1059 ||| JJ
patients  ||| S:1059 E:1068 ||| NNS
were  ||| S:1068 E:1073 ||| VBD
treated ||| S:1073 E:1080 ||| VBN
,  ||| S:1080 E:1082 ||| ,
and  ||| S:1082 E:1086 ||| CC
their  ||| S:1086 E:1092 ||| PRP$
results  ||| S:1092 E:1100 ||| NNS
were  ||| S:1100 E:1105 ||| VBD
examined  ||| S:1105 E:1114 ||| VBN
along  ||| S:1114 E:1120 ||| RP
with  ||| S:1120 E:1125 ||| IN
the  ||| S:1125 E:1129 ||| DT
original  ||| S:1129 E:1138 ||| JJ
cohort  ||| S:1138 E:1145 ||| NN
and  ||| S:1145 E:1149 ||| CC
were  ||| S:1149 E:1154 ||| VBD
compared  ||| S:1154 E:1163 ||| VBN
with  ||| S:1163 E:1168 ||| IN
historical  ||| S:1168 E:1179 ||| JJ
control  ||| S:1179 E:1187 ||| NN
subjects ||| S:1187 E:1195 ||| NNS
.  ||| S:1195 E:1197 ||| .
The  ||| S:1197 E:1201 ||| DT
device  ||| S:1201 E:1208 ||| NN
used  ||| S:1208 E:1213 ||| VBN
in  ||| S:1213 E:1216 ||| IN
this  ||| S:1216 E:1221 ||| DT
mode  ||| S:1221 E:1226 ||| NN
of  ||| S:1226 E:1229 ||| IN
treatment  ||| S:1229 E:1239 ||| NN
has  ||| S:1239 E:1243 ||| VBZ
not  ||| S:1243 E:1247 ||| RB
been  ||| S:1247 E:1252 ||| VBN
approved  ||| S:1252 E:1261 ||| VBN
for  ||| S:1261 E:1265 ||| IN
use  ||| S:1265 E:1269 ||| NN
in  ||| S:1269 E:1272 ||| IN
the  ||| S:1272 E:1276 ||| DT
general  ||| S:1276 E:1284 ||| JJ
spinal  ||| S:1284 E:1291 ||| JJ
cord-injured  ||| S:1291 E:1304 ||| JJ
population ||| S:1304 E:1314 ||| NN
,  ||| S:1314 E:1316 ||| ,
pending  ||| S:1316 E:1324 ||| VBG
further  ||| S:1324 E:1332 ||| JJ
study ||| S:1332 E:1337 ||| NN
.  ||| S:1337 E:1339 ||| .
A  ||| S:1339 E:1341 ||| DT
larger  ||| S:1341 E:1348 ||| JJR
multi-institutional  ||| S:1348 E:1368 ||| JJ
trial  ||| S:1368 E:1374 ||| NN
needs  ||| S:1374 E:1380 ||| VBZ
to  ||| S:1380 E:1383 ||| TO
be  ||| S:1383 E:1386 ||| VB
done  ||| S:1386 E:1391 ||| VBN
to  ||| S:1391 E:1394 ||| TO
further  ||| S:1394 E:1402 ||| RBR
demonstrate  ||| S:1402 E:1414 ||| JJ
efficacy  ||| S:1414 E:1423 ||| NN
and  ||| S:1423 E:1427 ||| CC
effectiveness ||| S:1427 E:1440 ||| NN
,  ||| S:1440 E:1442 ||| ,
and  ||| S:1442 E:1446 ||| CC
outcomes  ||| S:1446 E:1455 ||| NNS
will  ||| S:1455 E:1460 ||| MD
need  ||| S:1460 E:1465 ||| VB
to  ||| S:1465 E:1468 ||| TO
be  ||| S:1468 E:1471 ||| VB
agreed  ||| S:1471 E:1478 ||| VBN
upon  ||| S:1478 E:1483 ||| RP
by  ||| S:1483 E:1486 ||| IN
spinal  ||| S:1486 E:1493 ||| JJ
cord  ||| S:1493 E:1498 ||| NN
injury  ||| S:1498 E:1505 ||| NN
researchers ||| S:1505 E:1516 ||| NNS
,  ||| S:1516 E:1518 ||| ,
patients ||| S:1518 E:1526 ||| NNS
,  ||| S:1526 E:1528 ||| ,
and  ||| S:1528 E:1532 ||| CC
regulators  ||| S:1532 E:1543 ||| NNS
before  ||| S:1543 E:1550 ||| IN
widespread  ||| S:1550 E:1561 ||| JJ
use  ||| S:1561 E:1565 ||| NN
will  ||| S:1565 E:1570 ||| MD
be  ||| S:1570 E:1573 ||| VB
permitted ||| S:1573 E:1582 ||| VBN
.  ||| S:1582 E:1584 ||| .
Unfortunately ||| S:1584 E:1597 ||| RB
,  ||| S:1597 E:1599 ||| ,
some  ||| S:1599 E:1604 ||| DT
subtle  ||| S:1604 E:1611 ||| JJ
changes  ||| S:1611 E:1619 ||| NNS
experienced  ||| S:1619 E:1631 ||| VBN
and  ||| S:1631 E:1635 ||| CC
valued  ||| S:1635 E:1642 ||| VBN
by  ||| S:1642 E:1645 ||| IN
patients  ||| S:1645 E:1654 ||| NNS
are  ||| S:1654 E:1658 ||| VBP
not  ||| S:1658 E:1662 ||| RB
recognized  ||| S:1662 E:1673 ||| VBN
as  ||| S:1673 E:1676 ||| IN
important  ||| S:1676 E:1686 ||| JJ
or  ||| S:1686 E:1689 ||| CC
desirable  ||| S:1689 E:1699 ||| JJ
by  ||| S:1699 E:1702 ||| IN
regulators  ||| S:1702 E:1713 ||| NNS
or  ||| S:1713 E:1716 ||| CC
by  ||| S:1716 E:1719 ||| IN
all  ||| S:1719 E:1723 ||| DT
researchers ||| S:1723 E:1734 ||| NNS
.  ||| S:1734 E:1736 ||| .
